Combining Market Access Optimization and COGs Reduction to Secure ATMP Sustainability

Advanced Therapy Medicinal Products (ATMPs) are revolutionizing the treatment of a wide range of severe diseases. Their potential to deliver long-lasting or even curative effects places them at the forefront of biomedical innovation. However, despite their clinical promise, the successful development and widespread adoption of ATMPs face two critical hurdles: high manufacturing costs and market access specificities.

To ensure these transformative therapies deliver their clinical benefits to all eligible patients in a sustainable way both for healthcare systems and innovators, a combined approach that integrates cost-efficiency strategies with early and evidence-based market access planning are critical.

Join us for a focused discussion on how combining market access strategies with smart manufacturing cost (COGs) management can support funding, successful development, and commercialization of ATMPs. Marc-Olivier Mignon, President of CELLforCURE by Seqens, will discuss together with Sandrine Bourguignon, CEO of Rweality, an Enosium Life Science company.

During this webinar we will discuss:

• The most common market access barriers for ATMPs
• How to handle manufacturing challenges through early and integrated planning
• Insights from both the manufacturing and market access perspectives

Speakers :

• Marc-Olivier Mignon – President of CELLforCURE by Seqens

Marc-Olivier Mignon, with more than 20 years in the pharma industry at MSD, Novartis and Alexion Pharmaceuticals, has built a remarkable experience in launching innovations on a large range of products, geographical and therapeutic area, paving the way for sustainable and profitable businesses. More recently, from 2018 to 2022, Marc-Olivier Mignon was instrumental in the commercialization of the first CAR-T cells on the French market, setting up from scratch, with his Team, a totally new commercialization model. Marc-Olivier Mignon is a certified Doctor in Veterinary Medicine and holds a Master Degree in Pharmacology.

• Sandrine Bourguignon – CEO of Rweality

Sandrine Bourguignon, PhD in Public Health and Health Economics, is the CEO of Rweality and Vyoo, two companies respectively specialized in public policy evaluation and market access, and in health economic assessment. With over 20 years of experience as a consultant in health economics, Sandrine has developed strong expertise in supporting healthcare innovation strategies. She is also a lecturer at Paris-Dauphine University and the Conservatoire national des arts et métiers (Cnam).